Dendritic cell-based immunotherapy for hepatocellular carcinoma

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 3, 2010, Pages 413-416

  Nakamoto, Yasunari ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Dendritic cells; Hepatocellular carcinoma; Immunotherapy

Indexed keywords

CD83 ANTIGEN; PICIBANIL;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL EMBOLISM; DENDRITIC CELL; HEPATITIS C; IMMUNOTHERAPY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MONOCYTE;

EID: 79960763606     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Albert ML, Sauter B and Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392: 86-89, 1998. (Pubitemid 28150594)
2. Obeid M, Tesniere A, Ghiringhelli F, et al: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61, 2007. (Pubitemid 46067386)
3. Nakamoto Y, Mizukoshi E, Tsuji H, et al: Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin Exp Immunol 147: 296-305, 2007.
4. Gilboa E: DC-based cancer vaccines. J Clin Invest 117: 1195-1203, 2007.
5. Ferrantini M, Capone I and Belardelli F: Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev 19: 93-107, 2008. (Pubitemid 351200063)